VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Uncover the untold love story of astronaut Sally Ride. "Sally" premieres June 16 on National Geographic and the next day on Hulu and Disney+.

John Murray has acquired Sally Magnusson’s Orkney-set novel based on the Old Norse myth of Hel, titled The Shapeshifter’s Daughter.

Astronomy interviews Sally Ride's life partner Tam O’Shaughnessy and director Cristina Costantini ahead of 'Sally' documentary release June 16.

Normally dry areas near the coast will be flooded by rising waters moving inland from the shoreline due to Hurricane Sally, according to the NHC.

Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter earnings call.

A new study reconsiders the controversial findings of NASA's Viking Mars lander in 1976, which some argue may have shown signs of past life on the Red Planet.

Here’s how the company can scale up. Viking’s obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups.

Viking Global Investors makes bold bets in finance sector with top holdings in US Bancorp, Visa, and Progressive Corp. Long-term growth strategy pays off.

Merck partners with Hansoh Pharma for GLP-1 drug development, while analysts highlight Viking's obesity assets as key for future growth.

Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a compelling buy with blockbuster potential.

Dirk Schulze-Makuch is a scientist who thinks NASA's Viking landers could have inadvertently destroyed the life they were searching for. In this Q&A, we ask why.